Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thyroid hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    227 result(s) found for: Thyroid hormone. Displaying page 6 of 12.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2018-002790-22 Sponsor Protocol Number: ML39921 Start Date*: 2019-04-11
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: Tocilizumab in Graves’ Orbitopathy (TOGO). Multicenter, randomized, observer-blind, controlled study of the anti-IL-6 receptor antibody tocilizumab (TCZ) or methylprednisolone (MP) treatment in pat...
    Medical condition: Active moderate-severe Graves' Orbitopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10015684 Exophthalmos endocrine LLT
    20.1 100000004853 10014702 Endocrine exophthalmos LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004670-24 Sponsor Protocol Number: SYR-322-PLC-010 Start Date*: 2006-05-26
    Sponsor Name:Takeda Global Research & Development Center, Inc.
    Full Title: A multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and safety of SYR110322 (SYR-322) Compared with Placebo in Subjects with Type 2 Diabetes
    Medical condition: Type II diabetes mellitus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-001638-41 Sponsor Protocol Number: CLAR-09007 Start Date*: 2011-10-12
    Sponsor Name:CLARUS THERAPEUTICS, INC.
    Full Title: PHASE III, ACTIVE-CONTROLLED, SAFETY AND EFFICACY TRIAL OF ORAL TESTOSTERONE UNDECANOATE (TU) IN HYPOGONADAL MEN.
    Medical condition: Hypogonadal men
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001684-21 Sponsor Protocol Number: NV1205-009 Start Date*: 2018-04-20
    Sponsor Name:Neurov Acquisition LLC
    Full Title: Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)
    Medical condition: Childhood Cerebral Adrenoleukodystrophy (CCALD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Prematurely Ended) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-004594-32 Sponsor Protocol Number: IO102-IO103-013/MK3475-D18 Start Date*: 2022-02-16
    Sponsor Name:IO Biotech ApS
    Full Title: An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (adv...
    Medical condition: Patients with previously untreated, unresectable or metastatic (advanced) melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) IE (Prematurely Ended) BE (Trial now transitioned) HU (Trial now transitioned) PT (Completed) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002993-29 Sponsor Protocol Number: M13-625 Start Date*: 2015-07-15
    Sponsor Name:Abbott Laboratories GmbH
    Full Title: A Randomized, Open-label, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg daily versus Crinone 8% intravaginal progesterone gel 90 mg daily ...
    Medical condition: Treatment for the luteal support in in-vitro fertilization (IVF).
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004865 10021572 In vitro fertilization LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006114-14 Sponsor Protocol Number: 62326B1658 Start Date*: 2012-04-17
    Sponsor Name:Research and Development department
    Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr...
    Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-001295-36 Sponsor Protocol Number: SRM105106 Start Date*: 2007-08-22
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 ad...
    Medical condition: Treatment of moderate to extremely severe vasomotor symptoms in healthy postmenopausal women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-002215-26 Sponsor Protocol Number: M13-563 Start Date*: 2013-07-18
    Sponsor Name:Abbott Laboratories GmbH
    Full Title: A Double-Blind, Double-Dummy, Randomized, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg daily versus Intravaginal Micronized Progesterone C...
    Medical condition: Female infertility
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004865 10003540 Assisted fertilization LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) AT (Completed) ES (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2012-005374-57 Sponsor Protocol Number: Calcimimetics Start Date*: 2013-02-15
    Sponsor Name:Department of Breast and Endocrine Surgery, Karolinska University Hospital
    Full Title: Primary hyperparathyroidism: Short-term calcimimetics treatment – Relevance for parathyroid surgery decisions?
    Medical condition: Primary hyperparathyroidism (PHPT) is a common disease, characterized by a high-normal calcium concentration and an inappropriately increased parathyroid hormone (PTH) level
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004860 10036693 Primary hyperparathyroidism LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002389-62 Sponsor Protocol Number: 8-55-52030-309 Start Date*: 2015-03-02
    Sponsor Name:Ipsen Group
    Full Title: Phase IIa, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of lanreotide PRF in subjects wi...
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10000599 Acromegaly PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) NL (Completed) CZ (Completed) LT (Completed) ES (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003768-29 Sponsor Protocol Number: DAY101-102 Start Date*: 2022-04-05
    Sponsor Name:DOT Therapeutics-1 Inc. (Day One)
    Full Title: A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
    Medical condition: Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-004425-27 Sponsor Protocol Number: 5863 Start Date*: 2012-05-29
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: Study of Optimal Replacement of Thyroxine in the ElDerly (SORTED) SORTED 1 – a Randomised Controlled Trial (Pilot study) SORTED 2 – Qualitative Interviews SORTED 3 – Retrospective Cohort
    Medical condition: hypothyroidism (elderly individuals)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000488-83 Sponsor Protocol Number: P03685 Start Date*: 2004-11-29
    Sponsor Name:Schering Plough Research Institute, a Division of Schering Corporation
    Full Title: A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response
    Medical condition: Chronic Hepatitis C, Genotype 1
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) HU (Completed) LT (Completed) CZ (Completed) AT (Completed) DK (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001969-27 Sponsor Protocol Number: GLP111892 Start Date*: 2014-11-19
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016051-22 Sponsor Protocol Number: CL004_140 Start Date*: 2010-02-09
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus in subjects with insufficient glycemic control on a stable dose of metformin
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-001810-13 Sponsor Protocol Number: GSN000350 Start Date*: 2021-12-11
    Sponsor Name:Genkyotex Suisse SA
    Full Title: TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elev...
    Medical condition: Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
    Disease: Version SOC Term Classification Code Term Level
    21.0 10019805 - Hepatobiliary disorders 10080429 Primary biliary cholangitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) AT (Completed) FR (Completed) ES (Prematurely Ended) PL (Completed) IT (Completed) GR (Completed) SE (Completed) CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000797-30 Sponsor Protocol Number: SPI-IIT-002 Start Date*: 2013-10-08
    Sponsor Name:Department of Medical Research, Odense University Hospital, Svendborg Hospital
    Full Title: Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation
    Medical condition: Paroxysmal and persistent atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10071667 Persistent atrial fibrillation LLT
    18.1 100000004849 10066664 Recurrent symptomatic atrial fibrillation LLT
    18.1 100000004849 10003661 Atrial fibrillation paroxysmal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000103-16 Sponsor Protocol Number: SEP380-201 Start Date*: 2018-11-26
    Sponsor Name:SUNOVION PHARMACEUTICALS INC.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated with Bipolar I Disorder
    Medical condition: Major Depressive Episodes Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-019765-28 Sponsor Protocol Number: SP0993 Start Date*: 2011-02-08
    Sponsor Name:UCB BIOSCIENCES GmbH
    Full Title: A MULTICENTER, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, POSITIVE CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) TO CONTROLLED RELEASE CARBAMAZEPINE (400 TO 1200M...
    Medical condition: Epilepsy, partial onset or generalised tonic-clonic seizures.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) FI (Completed) SE (Completed) HU (Completed) ES (Completed) PT (Completed) PL (Completed) SK (Completed) GB (Completed) GR (Completed) IT (Completed) LV (Completed) LT (Completed) BG (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 26 02:18:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA